PMID- 29229594
OWN - NLM
STAT- MEDLINE
DCOM- 20190319
LR  - 20240207
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 11
DP  - 2018 Mar 15
TI  - Interim results of brentuximab vedotin in combination with nivolumab in patients 
      with relapsed or refractory Hodgkin lymphoma.
PG  - 1183-1194
LID - 10.1182/blood-2017-10-811224 [doi]
AB  - In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) 
      administered in combination were evaluated as initial salvage therapy in patients 
      with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients 
      received up to 4 cycles of combination treatment, with BV administered on day 1 
      and Nivo on day 8 of the first cycle. For cycles 2 to 4, BV and Nivo were both 
      administered on day 1. After study treatment, responses were evaluated by 
      investigators per the 2014 Lugano classification, and patients could proceed to 
      autologous stem cell transplantation (ASCT). Sixty-two patients were enrolled; 
      the complete response rate among all treated patients (n = 61) was 61%, with an 
      objective response rate of 82%. Before ASCT, adverse events (AEs) occurred in 98% 
      of patients, mostly grades 1 and 2. Infusion-related reactions (IRRs) occurred in 
      44% of patients overall, with 41% of patients experiencing an IRR during at least 
      1 infusion of BV. Five patients (8%) were treated with systemic steroids for 
      immune-related AEs. A reduction of peripheral T-cell subsets including regulatory 
      T cells was observed after the first dose of BV, and reduced serum levels of 
      thymus- and activation-regulated chemokine concurrent with an increase in 
      proinflammatory cytokines and chemokines were seen after the first BV plus Nivo 
      infusions. The combination of BV plus Nivo was an active and well-tolerated first 
      salvage regimen, potentially providing patients with R/R HL an alternative to 
      traditional chemotherapy. This trial was registered at www.clinicaltrials.gov as 
      #NCT02572167.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Herrera, Alex F
AU  - Herrera AF
AD  - City of Hope National Medical Center, Duarte, CA.
FAU - Moskowitz, Alison J
AU  - Moskowitz AJ
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Bartlett, Nancy L
AU  - Bartlett NL
AD  - Division of Hematology and Oncology, Washington University School of Medicine, 
      St. Louis, MO.
FAU - Vose, Julie M
AU  - Vose JM
AD  - University of Nebraska Medical Center, Omaha, NE.
FAU - Ramchandren, Radhakrishnan
AU  - Ramchandren R
AD  - Karmanos Cancer Institute, Detroit, MI.
FAU - Feldman, Tatyana A
AU  - Feldman TA
AD  - Hackensack University Medical Center, Hackensack, NJ.
FAU - LaCasce, Ann S
AU  - LaCasce AS
AD  - Dana-Farber Cancer Institute, Boston, MA.
FAU - Ansell, Stephen M
AU  - Ansell SM
AD  - Mayo Clinic, Rochester, MN.
FAU - Moskowitz, Craig H
AU  - Moskowitz CH
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Fenton, Keenan
AU  - Fenton K
AD  - Seattle Genetics, Inc, Bothell, WA.
FAU - Ogden, Carol Anne
AU  - Ogden CA
AD  - Seattle Genetics, Inc, Bothell, WA.
FAU - Taft, David
AU  - Taft D
AD  - Seattle Genetics, Inc, Bothell, WA.
FAU - Zhang, Qu
AU  - Zhang Q
AD  - Seattle Genetics, Inc, Bothell, WA.
FAU - Kato, Kazunobu
AU  - Kato K
AD  - Bristol-Myers Squibb, Princeton, NJ; and.
FAU - Campbell, Mary
AU  - Campbell M
AD  - Seattle Genetics, Inc, Bothell, WA.
FAU - Advani, Ranjana H
AU  - Advani RH
AD  - Stanford University Medical Center, Palo Alto, CA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02572167
GR  - K12 CA001727/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P50 CA107399/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171211
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Chemokines)
RN  - 0 (Immunoconjugates)
RN  - 31YO63LBSN (Nivolumab)
RN  - 7XL5ISS668 (Brentuximab Vedotin)
SB  - IM
CIN - Blood. 2018 Mar 15;131(11):1156-1157. PMID: 29545402
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Brentuximab Vedotin
MH  - Chemokines/blood
MH  - Female
MH  - Hodgkin Disease/blood/*drug therapy/pathology
MH  - Humans
MH  - Immunoconjugates/administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/administration & dosage/adverse effects
MH  - Recurrence
MH  - T-Lymphocytes, Regulatory/metabolism/pathology
PMC - PMC5855021
COIS- Conflict-of-interest disclosure: K.F., C.A.O., D.T., Q.Z., and M.C. are employees 
      of and receive equity ownership in Seattle Genetics, Inc. A.F.H. received 
      research funding from Seattle Genetics, Bristol-Myers Squibb, MedImmune, Merck, 
      Immune Design, Genentech, and Pharmacyclics. A.J.M. received research funding 
      from Seattle Genetics. N.L.B. received research funding from Seattle Genetics, 
      Janssen, Affimed, ImaginAb, KITE, Forty Seven, Pharmacyclics, Celgene, 
      Bristol-Myers Squibb, AstraZeneca, Genentech, Merck, Millennium, Pfizer, Immune 
      Design, and Novartis. J.M.V. received research funding from Seattle Genetics, 
      Bristol-Myers Squibb, Onyx, Merck, KITE, Janssen, Celgene, Allos Therapeutics, 
      Acerta, Incyte, and US Biotest. R.R., T.A.F., and A.S.L. received research 
      funding from Seattle Genetics. S.M.A. received research funding from Seattle 
      Genetics and Merck. C.H.M. received research funding from Seattle Genetics, 
      Pharmacyclics, and Merck. R.H.A. received research funding from Seattle Genetics, 
      Agensys, Bristol-Myers Squibb, Celgene, Genentech, Infinity, Kura, Merck, 
      Millennium, Regeneron, Janssen, and Pharmacyclics. A.F.H. has consulted for 
      Merck, Genentech, Bristol-Myers Squibb, and Pharmacyclics. N.L.B. has consulted 
      for Seattle Genetics, Gilead, and KITE. R.R. has consulted for Seattle Genetics. 
      C.H.M. has consulted for Seattle Genetics, Celgene, Genentech, and Merck. R.H.A. 
      has consulted for Gilead, Spectrum, Bristol-Myers Squibb, Pharmacyclics, 
      NanoString, Forty Seven, Sutro, and Juno Therapeutics. T.A.F. is a member of a 
      speakers bureau for Seattle Genetics, Pharmacyclics, Johnson & Johnson, AbbVie, 
      and Celgene. The remaining author declares no competing financial interests.
EDAT- 2017/12/13 06:00
MHDA- 2019/03/20 06:00
PMCR- 2018/03/15
CRDT- 2017/12/13 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2018/03/15 00:00 [pmc-release]
AID - S0006-4971(20)32398-3 [pii]
AID - 2017/811224 [pii]
AID - 10.1182/blood-2017-10-811224 [doi]
PST - ppublish
SO  - Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 
      2017 Dec 11.